Orchard Therapeutics (Europe) Limited
- Address
- 245 Hammersmith Road
Sponsor Overview
Specializations
Metachromatic Leukodystrophy and related lysosomal storage disorders
Orchard Therapeutics (Europe) Limited supports clinical research in Metachromatic Leukodystrophy, including late juvenile MLD and broader ARSA deficiency manifestations. The funded studies focus on neurological outcomes, disease progression, and restoration of enzyme activity in affected tissues.
- MLD
- Late juvenile MLD
- Motor impairment
- Residual ARSA activity
Research activity in this area is centered on gene therapy approaches designed for inherited neurodegenerative disease.
Mucopolysaccharidosis type I and Hurler syndrome
The sponsor funds studies in Mucopolysaccharidosis type I, including the severe childhood form known as Hurler syndrome. These trials examine treatment options aimed at addressing the underlying metabolic defect and supporting clinical benefit in pediatric patients.
- MPS-IH
- Hurler syndrome
- IDUA gene
- Pediatric lysosomal disease
Clinical interest in this domain includes autologous hematopoietic stem cell approaches for inherited metabolic disorders.
Hematopoietic stem cell gene therapy
Orchard Therapeutics focuses on hematopoietic stem cell-based gene therapy programs that use genetically modified autologous cells to treat inherited diseases. The clinical portfolio includes investigations of cell-enriched products and lentiviral vector-enabled gene delivery.
- Autologous CD34+ cells
- HSPC transduction
- Lentiviral vector
- Cell-based gene transfer
These studies reflect a strong therapeutic interest in correcting inherited enzyme deficiencies through ex vivo cellular engineering.
Neurological and motor function outcomes
The sponsor’s trials place emphasis on neurological disease burden, including central nervous system involvement, peripheral nervous system involvement, and changes in functional performance. Outcomes include clinical measures of motor impairment and disease-related disability in children and young people.
- Clinical motor impairment
- GMFM scoring
- Neurological progression
- Functional disability
This area links the sponsor’s work to disorders where preserving movement, coordination, and neurological function is central to treatment evaluation.
Sponsored Trials
Data & Insights
This sponsor works with 8 molecules, of which 3 are not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Genetic Phenomena4 trials26 other sponsors
- 2.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial165 other sponsors
- 3.Musculoskeletal Diseases1 trial238 other sponsors
- 4.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
7 centres- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- 78 Rue Du General Leclerc, 94275 Le Kremlin-Bicetre
- Address
- Via Olgettina 60, 20132 Milan
- Address
- Heidelberglaan 25, 3584 CS Utrecht
- Address
- St. Johns, Fritz Bauers Gata 5, Malmo St. Johns, 214 28 Lund
- Address
- Otfried-Mueller-Strasse 10, Nordstadt, 72076 Tübingen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Orchard Therapeutics (Europe) Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.